## CLAIMS

1. A granule comprising a solid core on which is supported an active ingredient, said active ingredient being selected from gamma-hydroxybutric acid or one of its pharmaceutically acceptable salts,
said granule further comprising, supported on said solid core, the following compounds:
- one or more compounds which ~~may~~ generate gas evolvement,
- one or more diluents,
- a binder
- a coating membrane
said granule being characterized in that the solid core represents from 15% to 50% by weight based on the total weight of the granule.

2. The granule according to claim 1, wherein the solid core is selected from the group consisting of polyols, gums, derivatives of silica, calcium or potassium derivatives, mineral compounds such as dicalcium phosphates, tricalcium phosphates and calcium carbonates, saccharose, cellulose derivatives, notably microcrystalline cellulose, ethyl cellulose, and hydroxypropylmethylcellulose, starch and mixtures thereof.

3. The granule according to one of claims 1 or 2, wherein the diluent is selected from silica derivatives, and notably derivatives of magnesium aluminometasilicate.

4. The granule according to any of claims 1 to 3, wherein the compound which may generate gas evolvement is selected from the group consisting of carbonate and bicarbonates, and is notably selected from the group consisting of sodium bicarbonate, sodium carbonate, sodium glycine carbonate, potassium bicarbonate, magnesium carbonate and calcium carbonate.

5. The granule according to an of claims 1 to 4, wherein the membrane consists of coating excipients for immediate release.

6. The granule according to any of claims 1 to 4, wherein the membrane consists of coating excipients for sustained release.

7. The granule according to any of claims 1 to 6 characterized in that it consists of:

- 15-25% of solid core,
- 50-60% of active ingredient
- 5-15% of sodium bicarbonate, a gas generator
- 2-18% of ~~Neusilin®~~magnesium aluminometasilicate, diluent
- 3-10% of shellac, a binder
- 3-6% of coating membrane

8. The granule according to any of claims 1 to 7 characterized in that it further comprises a coloring agent.

9. The granule according to any of claims 1 to 8, in that it further comprises a sweetener.

10. The granule according to any of claims 1 to 9, characterized in that it further comprises a flavoring agent.

11. A pharmaceutical composition comprising a mixture of granules according to any of claims 1 to 10, wherein said mixture consists of two groups of granules (A) and (B), the granules (A) and the granules (B) having different kinetics for releasing the active ingredient.

12. Use of the granule according to any of claims 1 to 11 in the manufacture of a medicament for treating pathologies requiring at least ~~very fast~~ 85% in less than 5 minutes *in vivo* availability of GHB.

13. Use of the granule according to claim 12, wherein the pathology is narcolepsy.

14. Use of the granule according to claim 12, wherein the pathology is alcoholic withdrawal.